시장보고서

상품코드

1454140

파클리탁셀 주사 시장 : 적응증별, 용도별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Paclitaxel Injection Market, By Indication Type, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 03월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 311 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

파클리탁셀 주사 시장 규모는 2023년 61억 452만 달러로 평가되었고, 2024년부터 2032년까지 연평균 복합 성장률(CAGR) 12.90%로 확대될 것으로 예상됩니다.

파클리탁셀 주사 시장 역학

암 환자 수 증가가 시장 성장을 가속할 것으로 예상됩니다.

암 환자 수는 계속 증가하고 있으며, 암은 전 세계적으로 큰 건강 문제로 대두되고 있습니다. 인구 고령화, 생활습관 변화, 환경적 영향, 암 발견 및 진단의 발전 등 다양한 요인이 전 세계 암 유병률 증가에 영향을 미치고 있습니다. 미국 국립보건통계센터에 따르면, 2023년 미국에서 195만8310명의 암 환자가 새로 발생하고 60만9820명이 암으로 사망할 것으로 추정됩니다. 또한, 특히 신흥 경제국의 의료 인프라 개선으로 파클리탁셀 주사 시장이 확대될 것으로 예상되고 있습니다. 하지만 규제 이슈가 시장 성장을 저해할 수 있는 요인으로 작용할 수 있습니다.

파클리탁셀 주사 시장 - 주요 인사이트

당사의 리서치 애널리스트의 분석에 따르면, 세계 시장은 예측 기간(2024-2032) 동안 연평균 약 12.90%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

시장 세분화에 따르면, 2023년에는 유방암이 가장 큰 시장 점유율을 보일 것으로 예상됩니다.

용도별로는 2023년 병원이 주요 유형으로 나타났습니다.

지역별로는 북미가 2023년 매출 1위

파클리탁셀 주사 시장 - 세분화 분석 :

파클리탁셀 주사 세계 시장은 적응증 유형, 용도 및 지역에 따라 세분화됩니다.

시장은 적응증 유형에 따라 전립선암, 유방암, 비소세포폐암, 에이즈 관련 카포시육종, 난소암, 위암, 자궁경부암, 식도암, 고환암, 폐암, 췌장암, 기타 등 11개 카테고리로 나뉩니다. 유방암이 시장에서 가장 큰 점유율을 차지하고 있습니다. 파클리탁셀은 유방암 치료에 널리 인정받고 일반적으로 사용되는 화학요법 약물입니다. 조기 유방암과 전이성 유방암을 포함한 다양한 유방암 아형에 대해 주요 암 치료 가이드라인에서 권장하는 표준 치료 요법의 일부입니다.

시장은 용도에 따라 암 연구센터, 병원, 기타 세 가지 부문으로 나뉩니다. 시장 성장을 주도하는 것은 주로 병원 부문입니다. 병원은 환자에게 화학요법 및 기타 암 치료를 제공하는 데 있어 매우 중요한 역할을 담당하고 있으며, 유방암을 비롯한 다양한 유형의 암에 대한 표준 치료로 파클리탁셀을 투여하고 있습니다.

파클리탁셀 주사 시장 - 지리적 통찰력

지역적으로 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카에 걸쳐 있습니다. 이 지역은 사업 활동에 기여하는 국가에 따라 더 세분화됩니다. 아시아태평양은 표적 치료에 대한 수요 증가로 인해 시장 성장을 주도할 것으로 예상됩니다. 건강한 조직에 대한 피해를 최소화하면서 암세포에 초점을 맞추는 표적 치료는 아시아태평양에서 인기를 끌고 있습니다. 파클리탁셀은 표적치료제와 병용하거나 정밀의료 접근법과 함께 사용되어 이러한 치료법의 효능을 향상시켜 시장 성장을 견인하고 있습니다. 중국에서만 30개 적응증에 20개 품목(25.6%)이 승인되었으며, 이 중 14개 품목(70.0%)이 2017년 이후 승인되었습니다. 미국 의사협회의 예측에 따르면 20개 품목 중 15개 품목(75.0%)이 표적치료제, 20개 품목 중 4개 품목(20.0%)이 면역치료제였습니다. 향후 유럽은 헬스케어 인프라에 대한 투자와 지출 증가로 인해 내년도 시장 성장률 2위를 차지할 것으로 예상됩니다.

파클리탁셀 주사 시장 - 경쟁 상황:

파클리탁셀 주사 공급업체 간의 경쟁은 규제, 경제, 기술, 상업적 요인이 복합적으로 작용하고 있습니다. 급변하는 헬스케어 산업에서 경쟁력을 확보하기 위해 제조업체는 이러한 역학관계를 전략적으로 관리해야 합니다. 파클리탁셀 주사 시장에서 경쟁사와의 차별화는 기술 혁신과 R&D 투자를 통해 이루어집니다. 제조업체는 치료 결과를 개선하고 환자의 편의성을 높이며 치료와 관련된 부작용을 최소화할 수 있는 새로운 제형, 전달 기술 또는 병용 요법을 개발할 수 있는 기회가 있습니다.

서론
북미
- 개요
- 북미 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제10장 주요 벤더 분석 파클리탁셀 주사 업계

경쟁 대시보드
기업 개요
- Pfizer
- Celgene Corporation
- Fresenius Kabi Oncology Ltd
- Abbott Laboratories
- Onco Therapies Ltd(Strides Arcolab Ltd.)
- Sagent Pharmaceuticals
- Bristol Myers Squibb
- Luye Pharma Group
- NOVASEP
- Others

제11장 애널리스트의 전방위 전망

LSH 24.04.30

REPORT HIGHLIGHT

Paclitaxel Injection Market size was valued at USD 6,104.52 Million in 2023, expanding at a CAGR of 12.90% from 2024 to 2032.

Paclitaxel is a chemotherapy medication designed to combat cancer by attacking fast-growing cancer cells. It is administered via injection and is typically prescribed for late-stage ovarian, breast, non-small cell lung cancer, and Kaposi sarcoma. Kaposi sarcoma, a type of cancer that impacts the skin and mucous membranes, is frequently diagnosed in individuals with AIDS. It is crucial that Paclitaxel (formulated with polyoxyethylated castor oil) injections are administered by a skilled oncologist in a hospital or medical setting.

Paclitaxel Injection Market- Market Dynamics

The rise in the number of cancer patients is expected to propel the market growth

Cancer poses a major worldwide health issue, as the number of cancer cases continues to increase. Various factors, including aging populations, lifestyle modifications, environmental influences, and advancements in cancer detection and diagnosis, all play a role in the rising prevalence of cancer globally. According to the National Center for Health Statistics, it is estimated that in 2023, there will be 1,958,310 new cases of cancer and 609,820 cancer-related deaths in the United States. Additionally, the growth of the paclitaxel injection market is expected to expand due to the improvement of healthcare infrastructure, especially in developing economies. Nevertheless, challenges in regulations may impede the market's growth.

Paclitaxel Injection Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 12.90% over the forecast period (2024-2032)

Based on Indication Type segmentation, Breast Cancer was predicted to show maximum market share in the year 2023

Based on application segmentation, Hospitals was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Paclitaxel Injection Market- Segmentation Analysis:

The Global Paclitaxel Injection Market is segmented on the basis of Indication Type, Application, and Region.

The market is segmented into eleven categories according to Indication Type: Prostate Cancer, Breast Cancer, Non-small Cell Lung Cancer, AIDS-related Kaposi's sarcoma, Ovarian Cancer, Stomach Cancer, Cervical Cancer, Esophageal Cancer, Testicular Cancer, Lung Cancer, Pancreatic Cancer, and Others. Breast Cancer holds the largest share in the market. Paclitaxel is a widely recognized and commonly used chemotherapy medication for treating breast cancer. It is part of the standard treatment regimens recommended by major cancer treatment guidelines for various subtypes of breast cancer, including early-stage and metastatic disease.

The market is categorized into three segments according to their application: Cancer Research Centers, Hospitals, and Others. The growth of the market is primarily driven by the hospital sector. Hospitals play a pivotal role in delivering chemotherapy and other cancer treatments to patients, which includes the administration of paclitaxel as a standard treatment for different types of cancer, such as breast cancer.

Paclitaxel Injection Market- Geographical Insights

Geographically, this market spans across North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further segmented by countries contributing to business activities. The Asia Pacific region is expected to lead the market growth, driven by the increasing demand for targeted therapies. Targeted therapies, which focus on cancer cells while minimizing harm to healthy tissues, are gaining popularity in the Asia Pacific region. Paclitaxel, when combined with targeted agents or used in precision medicine approaches, enhances the effectiveness of these therapies, thus boosting market expansion. In China alone, twenty drugs (25.6%) for 30 indications were approved, with 14 (70.0%) of them authorized after 2017; 15 out of 20 (75.0%) were targeted therapies, and 4 out of 20 (20.0%) were immunotherapies, as projected by the American Medical Association. Looking ahead, Europe is poised to become the second largest region for market growth in the upcoming year, thanks to increased investments in healthcare infrastructure and expenditures.

Paclitaxel Injection Market- Competitive Landscape:

The competition among suppliers of paclitaxel injection is influenced by a multifaceted combination of regulatory, economic, technological, and commercial factors. To establish a competitive edge in the ever-changing healthcare industry, manufacturers need to strategically navigate these dynamics. Competitive differentiation within the paclitaxel injection market is driven by innovation and investment in research and development. Manufacturers have the opportunity to develop new formulations, delivery technologies, or combination therapies that can enhance therapeutic outcomes, improve patient convenience, and minimize treatment-related side effects.

Recent Developments:

Pfizer has revealed the introduction of three new biosimilars, namely ZIRABEV (bevacizumab-bvzr), RUXIENCE (rituximab-pvvr), and TRAZIMERA (trastuzumab-qyyp) in the United States (U.S.). These medications are anticipated to be released at the most competitive Wholesale Acquisition Cost (WAC) compared to other bevacizumab, rituximab, or trastuzumab products currently in the market, offering a significantly reduced price compared to the original product.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PACLITAXEL INJECTION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Pfizer

Celgene Corporation

Fresenius Kabi Oncology Ltd

Abbott Laboratories

Onco Therapies Ltd (Strides Arcolab Ltd.)

Sagent Pharmaceuticals

Bristol Myers Squibb

Luye Pharma Group

NOVASEP

Others

GLOBAL PACLITAXEL INJECTION MARKET, BY INDICATION TYPE- MARKET ANALYSIS, 2019 - 2032

Prostate Cancer
Breast Cancer
Non-small Cell Lung Cancer
AIDS-related Kaposi's Sarcoma
Ovarian Cancer
Stomach Cancer
Cervical Cancer
Esophageal Cancer
Testicular Cancer
Lung Cancer
Pancreatic Cancer
Others

GLOBAL PACLITAXEL INJECTION MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

Cancer Research Centers
Hospital
Others

GLOBAL PACLITAXEL INJECTION MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1.Paclitaxel Injection Market Overview

1.1.Study Scope
1.2.Market Estimation Years

2.Executive Summary

2.1.Market Snippet
- 2.1.1.Paclitaxel Injection Market Snippet by Indication Type
- 2.1.2.Paclitaxel Injection Market Snippet by Application
- 2.1.3.Paclitaxel Injection Market Snippet by Country
- 2.1.4.Paclitaxel Injection Market Snippet by Region
2.2.Competitive Insights

3.Paclitaxel Injection Key Market Trends

3.1.Paclitaxel Injection Market Drivers
- 3.1.1.Impact Analysis of Market Drivers
3.2.Paclitaxel Injection Market Restraints
- 3.2.1.Impact Analysis of Market Restraints
3.3.Paclitaxel Injection Market Opportunities
3.4.Paclitaxel Injection Market Future Trends

4.Paclitaxel Injection Industry Study

4.1.PEST Analysis
4.2.Porter's Five Forces Analysis
4.3.Growth Prospect Mapping
4.4.Regulatory Framework Analysis

5.Paclitaxel Injection Market: COVID-19 Impact Analysis

5.1.Pre-COVID-19 Impact Analysis
5.2.Post-COVID-19 Impact Analysis
- 5.2.1.Top Performing Segments
- 5.2.2.Marginal Growth Segments
- 5.2.3.Top Looser Segments
- 5.2.4.Marginal Loss Segments

6.Paclitaxel Injection Market Landscape

6.1.Paclitaxel Injection Market Share Analysis, 2023
6.2.Breakdown Data, by Key Manufacturer
- 6.2.1.Established Players' Analysis
- 6.2.2.Emerging Players' Analysis

7.Paclitaxel Injection Market - By Indication Type

7.1.Overview
- 7.1.1.Segment Share Analysis, By Indication Type, 2023 & 2032 (%)
- 7.1.2.Prostate Cancer
- 7.1.3.Breast Cancer
- 7.1.4.Non-small Cell Lung Cancer
- 7.1.5.AIDS-related Kaposi's Sarcoma
- 7.1.6.Ovarian Cancer
- 7.1.7.Stomach Cancer
- 7.1.8.Cervical Cancer
- 7.1.9.Esophageal Cancer
- 7.1.10.Testicular Cancer
- 7.1.11.Lung Cancer
- 7.1.12.Pancreatic Cancer
- 7.1.13.Others

8.Paclitaxel Injection Market - By Application

8.1.Overview
- 8.1.1.Segment Share Analysis, By Application, 2023 & 2032 (%)
- 8.1.2.Cancer Research Centers
- 8.1.3.Hospital
- 8.1.4.Others

9.Paclitaxel Injection Market- By Geography

9.1.Introduction
- 9.1.1.Segment Share Analysis, By Geography, 2023 & 2032 (%)
9.2.North America
- 9.2.1.Overview
- 9.2.2.Paclitaxel Injection Key Manufacturers in North America
- 9.2.3.North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.2.4.North America Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
- 9.2.5.North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.2.6.U.S.
  - 9.2.6.1.Overview
  - 9.2.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.2.6.3.U.S. Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.2.6.4.U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.2.7.Canada
  - 9.2.7.1.Overview
  - 9.2.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.2.7.3.Canada Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.2.7.4.Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
9.3.Europe
- 9.3.1.Overview
- 9.3.2.Paclitaxel Injection Key Manufacturers in Europe
- 9.3.3.Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.3.4.Europe Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
- 9.3.5.Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.6.Germany
  - 9.3.6.1.Overview
  - 9.3.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.6.3.Germany Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.3.6.4.Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.7.Italy
  - 9.3.7.1.Overview
  - 9.3.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.7.3.Italy Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.3.7.4.Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.8.United Kingdom
  - 9.3.8.1.Overview
  - 9.3.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.8.3.United Kingdom Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.3.8.4.United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.9.France
  - 9.3.9.1.Overview
  - 9.3.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.9.3.France Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.3.9.4.France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.10.Russia
  - 9.3.10.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.10.2.Russia Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.3.10.3.Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.11.Netherlands
  - 9.3.11.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.11.2.Netherlands Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.3.11.3.Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.12.Sweden
  - 9.3.12.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.12.2.Sweden Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.3.12.3.Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.13.Poland
  - 9.3.13.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.13.2.Poland Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.3.13.3.Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.3.14.Rest of Europe
  - 9.3.14.1.Overview
  - 9.3.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.14.3.Rest of the Europe Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.3.14.4.Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
9.4.Asia Pacific (APAC)
- 9.4.1.Overview
- 9.4.2.Paclitaxel Injection Key Manufacturers in Asia Pacific
- 9.4.3.Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.4.4.Asia Pacific Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
- 9.4.5.Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.6.India
  - 9.4.6.1.Overview
  - 9.4.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.6.3.India Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.4.6.4.India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.7.China
  - 9.4.7.1.Overview
  - 9.4.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.7.3.China Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.4.7.4.China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.8.Japan
  - 9.4.8.1.Overview
  - 9.4.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.8.3.Japan Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.4.8.4.Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.9.South Korea
  - 9.4.9.1.Overview
  - 9.4.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.9.3.South Korea Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.4.9.4.South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.10.Australia
  - 9.4.10.1.Overview
  - 9.4.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.10.3.Australia Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.4.10.4.Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.11.Thailand
  - 9.4.11.1.Overview
  - 9.4.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.11.3.Thailand Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.4.11.4.Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.12.Indonesia
  - 9.4.12.1.Overview
  - 9.4.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.12.3.Indonesia Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.4.12.4.Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.13.Philippines
  - 9.4.13.1.Overview
  - 9.4.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.13.3.Philippines Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.4.13.4.Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.4.14.Rest of APAC
  - 9.4.14.1.Overview
  - 9.4.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.14.3.Rest of APAC Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.4.14.4.Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
9.5.Latin America
- 9.5.1.Overview
- 9.5.2.Paclitaxel Injection Key Manufacturers in Latin America
- 9.5.3.Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.5.4.Latin America Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
- 9.5.5.Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.5.6.Brazil
  - 9.5.6.1.Overview
  - 9.5.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.6.3.Brazil Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.5.6.4.Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.5.7.Mexico
  - 9.5.7.1.Overview
  - 9.5.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.7.3.Mexico Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.5.7.4.Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.5.8.Argentina
  - 9.5.8.1.Overview
  - 9.5.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.8.3.Argentina Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.5.8.4.Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.5.9.Colombia
  - 9.5.9.1.Overview
  - 9.5.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.9.3.Colombia Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.5.9.4.Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.5.10.Rest of LATAM
  - 9.5.10.1.Overview
  - 9.5.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.10.3.Rest of LATAM Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.5.10.4.Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
9.6.Middle East and Africa
- 9.6.1.Overview
- 9.6.2.Paclitaxel Injection Key Manufacturers in Middle East and Africa
- 9.6.3.Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.6.4.Middle East and Africa Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
- 9.6.5.Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.6.Saudi Arabia
  - 9.6.6.1.Overview
  - 9.6.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.6.3.Saudi Arabia Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.6.6.4.Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.7.United Arab Emirates
  - 9.6.7.1.Overview
  - 9.6.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.7.3.United Arab Emirates Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.6.7.4.United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.8.Israel
  - 9.6.8.1.Overview
  - 9.6.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.8.3.Israel Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.6.8.4.Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.9.Turkey
  - 9.6.9.1.Overview
  - 9.6.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.9.3.Turkey Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.6.9.4.Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.10.Algeria
  - 9.6.10.1.Overview
  - 9.6.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.10.3.Algeria Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.6.10.4.Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.11.Egypt
  - 9.6.11.1.Overview
  - 9.6.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.11.3.Egypt Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.6.11.4.Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 9.6.12.Rest of MEA
  - 9.6.12.1.Overview
  - 9.6.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.12.3.Rest of MEA Market Size and Forecast, By Indication Type, 2019 - 2032 (US$ Million)
  - 9.6.12.4.Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)

10.Key Vendor Analysis- Paclitaxel Injection Industry

10.1.Competitive Dashboard
10.2.Company Profiles
- 10.2.1.Pfizer
- 10.2.2.Celgene Corporation
- 10.2.3.Fresenius Kabi Oncology Ltd
- 10.2.4.Abbott Laboratories
- 10.2.5.Onco Therapies Ltd (Strides Arcolab Ltd.)
- 10.2.6.Sagent Pharmaceuticals
- 10.2.7.Bristol Myers Squibb
- 10.2.8.Luye Pharma Group
- 10.2.9.NOVASEP
- 10.2.10.Others

11.360 Degree Analyst View

12.Appendix

12.1.Research Methodology
12.2.References
12.3.Abbreviations
12.4.Disclaimer
12.5.Contact Us